Inovio Pharmaceuticals, Inc. Forecast, price target & analysts
Inovio Pharmaceuticals, Inc. Target price 2025 - Analyst rating & recommendation
Inovio Pharmaceuticals, Inc. Classifications & Recommendation:
Inovio Pharmaceuticals, Inc. Price Target
| Target Price | $9.50 |
| Price | $1.94 |
| Potential |
389.69%
register free of charge
|
| Number of Estimates | 6 |
|
6 Analysts have issued a price target Inovio Pharmaceuticals, Inc. 2026 .
The average Inovio Pharmaceuticals, Inc. target price is $9.50.
This is
389.69%
register free of charge
$18.00
827.84%
register free of charge
$3.00
54.64%
register free of charge
|
|
| A rating was issued by 6 analysts: 3 Analysts recommend Inovio Pharmaceuticals, Inc. to buy, 3 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Inovio Pharmaceuticals, Inc. stock has an average upside potential 2026 of
389.69%
register free of charge
|
Sales and Margin forecast 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Million $ | 0.83 | 0.13 |
| 91.91% | 83.92% | |
| Net Margin | -19,113.80% | -81,975.32% |
| 435.05% | 328.88% |
6 Analysts have issued a sales forecast Inovio Pharmaceuticals, Inc. 2024 . The average Inovio Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
1 Analyst has issued a net profit forecast Inovio Pharmaceuticals, Inc. 2024 . The average Inovio Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -6.09 | -4.20 |
| 56.72% | 31.03% | |
| P/E | negative | |
| EV/Sales | negative |
1 Analysts have issued a Inovio Pharmaceuticals, Inc. forecast for earnings per share. The average Inovio Pharmaceuticals, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Inovio Pharmaceuticals, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Inovio Pharmaceuticals, Inc....
Current Inovio Pharmaceuticals, Inc. Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Jan 13 2025 |
| JMP Securities | Locked ➜ Locked | Locked | Jan 10 2025 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Nov 18 2024 |
| Oppenheimer | Locked ➜ Locked | Locked | Nov 18 2024 |
| RBC Capital | Locked ➜ Locked | Locked | Nov 15 2024 |
| RBC Capital | Locked ➜ Locked | Locked | Oct 04 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Jan 13 2025 |
|
Locked
JMP Securities: Locked ➜ Locked
|
Jan 10 2025 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Nov 18 2024 |
|
Locked
Oppenheimer: Locked ➜ Locked
|
Nov 18 2024 |
|
Locked
RBC Capital: Locked ➜ Locked
|
Nov 15 2024 |
|
Locked
RBC Capital: Locked ➜ Locked
|
Oct 04 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
